Search research articles
Contact Us
Filters
Showing results (61-70 of 369) with videos related to
Page
of 37
Sort By:
The Journal of Biological Chemistry
|
April 5, 1992
Characterization of recombinant C1 inhibitor P1 variants
E Eldering, C C Huijbregts, Y T Lubbers, et al.
Blood
|
February 9, 2000
Extracellular granzyme A, complexed to proteoglycans, is protected against inactivation by protease inhibitors
E H Spaeny-Dekking, A M Kamp, C J Froelich, et al.
Blood
|
December 1, 1995
Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein
D M Ravon, F Citarella, Y T Lubbers, et al.
Clinical and Diagnostic Laboratory Immunology
|
November 1, 2001
Circulating inflammatory mediators in patients with fever: predicting bloodstream infection
A B Groeneveld, A W Bossink, G J van Mierlo, et al.
Immunology
|
July 1, 1987
Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor
J H Nuijens, C C Huijbregts, G M van Mierlo, et al.
Biochemistry
|
February 18, 1992
Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B
J D Becherer, J Alsenz, I Esparza, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 1, 1985
Low molecular weight C1q in systemic lupus erythematosus
R Hoekzema, A J Hannema, T J Swaak, et al.
Rheumatology International
|
January 1, 1988
Complement (C3) metabolism in rheumatoid arthritis in relation to the disease course
A J Swaak, H Han, A van Rooyen, et al.
Blood
|
August 15, 1997
Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2)
F Citarella, A Felici, M Brouwer, et al.
Clinical and Experimental Immunology
|
November 1, 1993
Neutrophil activation in ivermectin-treated onchocerciasis patients
F L Njoo, C E Hack, J Oosting, et al.
Page
of 37
Search research articles
Search
Showing results (61-70 of 369) with videos related to
Sort By:
Page
of 37
The Journal of Biological Chemistry
|
April 5, 1992
Characterization of recombinant C1 inhibitor P1 variants
E Eldering, C C Huijbregts, Y T Lubbers, et al.
Blood
|
February 9, 2000
Extracellular granzyme A, complexed to proteoglycans, is protected against inactivation by protease inhibitors
E H Spaeny-Dekking, A M Kamp, C J Froelich, et al.
Blood
|
December 1, 1995
Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein
D M Ravon, F Citarella, Y T Lubbers, et al.
Clinical and Diagnostic Laboratory Immunology
|
November 1, 2001
Circulating inflammatory mediators in patients with fever: predicting bloodstream infection
A B Groeneveld, A W Bossink, G J van Mierlo, et al.
Immunology
|
July 1, 1987
Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor
J H Nuijens, C C Huijbregts, G M van Mierlo, et al.
Biochemistry
|
February 18, 1992
Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B
J D Becherer, J Alsenz, I Esparza, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 1, 1985
Low molecular weight C1q in systemic lupus erythematosus
R Hoekzema, A J Hannema, T J Swaak, et al.
Rheumatology International
|
January 1, 1988
Complement (C3) metabolism in rheumatoid arthritis in relation to the disease course
A J Swaak, H Han, A van Rooyen, et al.
Blood
|
August 15, 1997
Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2)
F Citarella, A Felici, M Brouwer, et al.
Clinical and Experimental Immunology
|
November 1, 1993
Neutrophil activation in ivermectin-treated onchocerciasis patients
F L Njoo, C E Hack, J Oosting, et al.
Page
of 37